Glukagonlignende peptid 1-receptoragonisten semaglutid

Research output: Contribution to journalJournal articleResearchpeer-review

Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.

Original languageDanish
Article numberV03190155
JournalUgeskrift for Laeger
Number of pages5
Publication statusPublished - 2019

ID: 241276061